|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ATP5B |
Gene summary for ATP5B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ATP5B | Gene ID | 506 |
| Gene name | ATP synthase F1 subunit beta | |
| Gene Alias | ATP5B | |
| Cytomap | 12q13.3 | |
| Gene Type | protein-coding | GO ID | GO:0001503 | UniProtAcc | P06576 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 506 | ATP5B | NCCBC14 | Human | Breast | DCIS | 5.23e-11 | -3.52e-01 | 0.2021 |
| 506 | ATP5B | NCCBC3 | Human | Breast | DCIS | 7.93e-18 | -3.52e-01 | 0.1198 |
| 506 | ATP5B | NCCBC5 | Human | Breast | DCIS | 9.56e-11 | -3.52e-01 | 0.2046 |
| 506 | ATP5B | P1 | Human | Breast | IDC | 2.28e-11 | -3.52e-01 | 0.1527 |
| 506 | ATP5B | P2 | Human | Breast | IDC | 1.74e-07 | -3.52e-01 | 0.21 |
| 506 | ATP5B | DCIS2 | Human | Breast | DCIS | 1.53e-14 | -3.52e-01 | 0.0085 |
| 506 | ATP5B | HTA11_99999970781_79442 | Human | Colorectum | MSS | 6.71e-105 | 1.89e+00 | 0.294 |
| 506 | ATP5B | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 8.49e-22 | 3.04e+00 | 0.3487 |
| 506 | ATP5B | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.80e-47 | 1.15e+00 | 0.281 |
| 506 | ATP5B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.44e-112 | 2.27e+00 | 0.3859 |
| 506 | ATP5B | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.25e-41 | 1.13e+00 | 0.2585 |
| 506 | ATP5B | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.41e-57 | 9.52e-01 | 0.3005 |
| 506 | ATP5B | AEH-subject1 | Human | Endometrium | AEH | 3.38e-81 | -8.88e-01 | -0.3059 |
| 506 | ATP5B | AEH-subject2 | Human | Endometrium | AEH | 3.14e-67 | -8.88e-01 | -0.2525 |
| 506 | ATP5B | AEH-subject3 | Human | Endometrium | AEH | 3.38e-81 | -8.88e-01 | -0.2576 |
| 506 | ATP5B | AEH-subject4 | Human | Endometrium | AEH | 1.09e-53 | -8.88e-01 | -0.2657 |
| 506 | ATP5B | AEH-subject5 | Human | Endometrium | AEH | 3.38e-81 | -8.88e-01 | -0.2953 |
| 506 | ATP5B | EEC-subject1 | Human | Endometrium | EEC | 2.20e-79 | -8.88e-01 | -0.2682 |
| 506 | ATP5B | EEC-subject2 | Human | Endometrium | EEC | 2.20e-79 | -8.88e-01 | -0.2607 |
| 506 | ATP5B | EEC-subject3 | Human | Endometrium | EEC | 5.18e-77 | -8.88e-01 | -0.2525 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0501218 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502016 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501616 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019016 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501016 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501416 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502216 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520818 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471418 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541518 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| hsa0501219 | Breast | Precancer | Parkinson disease | 99/684 | 266/8465 | 3.58e-42 | 5.65e-40 | 4.33e-40 | 99 |
| hsa0502017 | Breast | Precancer | Prion disease | 95/684 | 273/8465 | 1.39e-37 | 1.46e-35 | 1.12e-35 | 95 |
| hsa0501617 | Breast | Precancer | Huntington disease | 98/684 | 306/8465 | 2.85e-35 | 2.25e-33 | 1.72e-33 | 98 |
| hsa0019017 | Breast | Precancer | Oxidative phosphorylation | 59/684 | 134/8465 | 6.15e-30 | 3.24e-28 | 2.48e-28 | 59 |
| hsa0501017 | Breast | Precancer | Alzheimer disease | 103/684 | 384/8465 | 1.03e-29 | 4.66e-28 | 3.57e-28 | 103 |
| hsa0501417 | Breast | Precancer | Amyotrophic lateral sclerosis | 98/684 | 364/8465 | 2.13e-28 | 8.41e-27 | 6.44e-27 | 98 |
| hsa0502217 | Breast | Precancer | Pathways of neurodegeneration - multiple diseases | 112/684 | 476/8465 | 6.96e-27 | 2.44e-25 | 1.87e-25 | 112 |
| hsa0520819 | Breast | Precancer | Chemical carcinogenesis - reactive oxygen species | 68/684 | 223/8465 | 3.61e-23 | 1.14e-21 | 8.73e-22 | 68 |
| hsa0471419 | Breast | Precancer | Thermogenesis | 68/684 | 232/8465 | 4.40e-22 | 1.26e-20 | 9.69e-21 | 68 |
| hsa0541519 | Breast | Precancer | Diabetic cardiomyopathy | 63/684 | 203/8465 | 5.63e-22 | 1.48e-20 | 1.14e-20 | 63 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ATP5B | SNV | Missense_Mutation | c.460N>A | p.Glu154Lys | p.E154K | P06576 | protein_coding | deleterious_low_confidence(0) | benign(0.323) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD | |
| ATP5B | SNV | Missense_Mutation | c.1030G>C | p.Glu344Gln | p.E344Q | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.977) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR | |
| ATP5B | deletion | Frame_Shift_Del | novel | c.1088delN | p.Pro363LeufsTer5 | p.P363Lfs*5 | P06576 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ATP5B | SNV | Missense_Mutation | rs2293450 | c.74N>T | p.Ser25Leu | p.S25L | P06576 | protein_coding | tolerated_low_confidence(0.78) | benign(0.005) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP5B | SNV | Missense_Mutation | novel | c.1360N>A | p.Val454Met | p.V454M | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.927) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ATP5B | SNV | Missense_Mutation | rs777770019 | c.1255N>A | p.Asp419Asn | p.D419N | P06576 | protein_coding | tolerated_low_confidence(0.5) | benign(0.001) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| ATP5B | SNV | Missense_Mutation | c.298G>A | p.Ala100Thr | p.A100T | P06576 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.75) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| ATP5B | SNV | Missense_Mutation | c.968N>A | p.Gly323Asp | p.G323D | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.957) | TCGA-D5-6927-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ATP5B | SNV | Missense_Mutation | c.992A>G | p.Tyr331Cys | p.Y331C | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.997) | TCGA-DM-A28E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| ATP5B | SNV | Missense_Mutation | c.1124N>T | p.Thr375Met | p.T375M | P06576 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-DM-A28G-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |